6
Aug
2020
COVID-19 Is Driving a Shift in How We Value Diagnostic Tests
There are very few things many of us can say with 100 percent certainty. But after three decades of experience in molecular diagnostics and the life science industry, I can say this: never before has the healthcare profession, and even the American public, been so laser-focused on diagnostics. For all the tragedy it has caused, the COVID-19 pandemic has shone... Read More
5
Aug
2020
Generation Bio Blazes New Trail in Gene Therapy with Non-Viral Approach
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2020
Versant Ventures Wagers $35M on Cytokine Engineering with Bright Peak
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2020
Akili Interactive Delivers Prescription Level Treatment via Video Games
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Aug
2020
Ohana Biosciences and Sperm Biology: The Other Half of the Fertility Equation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Jul
2020
Closing Medicine’s Feedback Gap: Can Tech Help Integrate Clinical Care and Clinical Research?
Medicine is plagued by a feedback gap, or perhaps more accurately, a feedback paradox. On the one hand, clinicians are bombarded by feedback. Every day, there are a slew of process and billing metrics to review, providing an accounting of the volume of patients seen, and the intensity of each visit. How thorough was the exam? What procedures may have... Read More
30
Jul
2020
Jill Hagenkord’s Rags To Riches Story Reminds Us Why We Still Admire Entrepreneurs
Entrepreneurial stories, often told through the narrative framework of the hero’s journey, are by now well past the point of cliché. Yet, it’s important, perhaps even instructive, to remind ourselves every now and again about the exceptional, transformative power of entrepreneurship, the can-do thinking it motivates, and the remarkable progress it can propel. This potential emerged as a central theme... Read More
30
Jul
2020
Race and Life Sciences: Where is the Healing?
When I started to go to the J.P. Morgan Healthcare Conference, it was still known as H&Q after boutique bank Hambrecht & Quist that had originated it. This means that, as a journalist, I have been able to watch biopharma grow up over the last 20 years. Those first few events I attended had so little diversity that the upstairs... Read More
23
Jul
2020
Pfizer Secures $2B for COVID-19 Vaccine, BioNTech Raises $500M, & Our Test
When Donald Trump first considered a run for president in 2000, he never rose above 1 percent in the polls. America changed in the early years of the 21st century. Trump was always good at harnessing tabloid media weaknesses to his advantage. When our information commons shifted to a 24/7 advertising-based attention-grab economy on the Internet and TV, he was... Read More
23
Jul
2020
When Raising Drug Prices Helps Patients
Sometimes there are good, patient-friendly reasons to raise drug prices. Proposed legislation that aims to eliminate price hikes on prescription drugs will have unintended consequences. San Francisco-based Jaguar Health, for two years in a row, lost more than $30 million a year. Revenue from its only product, a diarrhea treatment for HIV patients, was only $5.8 million in 2019. The... Read More
22
Jul
2020
Adaptive Trials: Pioneered in the US, Implemented in the UK for COVID-19
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jul
2020
Seer Raises $55 Million; Describes Novel Proteomic Technology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Jul
2020
The Road Less Traveled in Biotech: Abe Ceesay on The Long Run
Today’s guest on The Long Run is Abe Ceesay. He’s the CEO of Cambridge, Mass.-based Tiburio Therapeutics. The company is developing a couple of drug candidates for rare neuroendocrine tumors. It raised $31 million in a Series A financing in January 2019 from NEA, Lundbeckford Ventures, Longitude Capital, and Alexandria Real Estate Equities. Abe is in his early 40s, and... Read More
20
Jul
2020
Barring Foreign Talent Is An Assault on Biotech Innovation
As a first generation American (John Maraganore) and a proud immigrant (Jeremy Levin), we’re appalled by the relentless, short-sighted assaults by this Administration on legal immigration. The latest attempt specifically aims to limit, and potentially shut down, immigration to America of the world’s best and brightest minds. This is precisely the time we need these bright minds. Thankfully, in light... Read More
20
Jul
2020
Clinical Trials: High-Value Attack Surface For Pharmatech Entrepreneurs
There’s an emerging sense among early stage investors that there are profound opportunities at the intersection of healthcare and technology, and no shortage of white papers from consultants and venture groups addressing this topic. Consultant white papers tend to be focused on the inevitability of “digital transformation,” emphasize the $X billion dollar opportunity, and argue that if large organizations don’t... Read More
20
Jul
2020
Karuna Therapeutics Innovates in Schizophrenia Treatment with Hybrid Drug
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jul
2020
Standing With Fauci, Positive Moderna Vaccine Data, and Blueprint’s Megadeal
Last week in these pages, I wrote a full-throated defense of Tony Fauci. A few days later, the White House sadly started doing what it so often does. It embarked on a dirty tricks smear campaign against someone who speaks inconvenient truth to the public. Peter Navarro, who doesn’t know what he’s talking about when it comes to public health... Read More
15
Jul
2020
Do We Need Models Anymore?
Long ago, in the early days of the pandemic, models were everywhere in the news. As our lives were upended and everything became uncertain, models were there to provide some predictability in the face of the unknown. Never mind that predictions varied wildly – between models, and even within the same model at different time points. The models agreed that... Read More
15
Jul
2020
Next-gen Synthetic Biology Pushes Further Into Drug Discovery, mRNA and DNA on the Desktop
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jul
2020
Ovid Therapeutics Finds European Partner to Advance Treatment for Rare Neurological Disease
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.